Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Growth inhibition of prostate cancer xenografts by halofuginone.

The Prostate - 1 May 2002

Gavish Zohar, Pinthus Jehonathan H, Barak Vivian, Ramon Jacob, Nagler Arnon, Eshhar Zelig, Pines Mark

Abstract excerpt

BACKGROUND: Halofuginone, an inhibitor of collagen type I synthesis, is an anti-angiogenic agent. Here we evaluated the efficacy of halofuginone to inhibit prostate cancer (PC) xenografts representing various phenotypes of the disease. METHODS: An androgen-dependent (CWR22), an androgen-independent (PC3), and a neuroendocrine (WISH-PC2) PC xenograft were used. Halofuginone was given orally or injected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Androgens
Share to Collagen Type I

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Injections, Intraperitoneal

Share to Necrosis

Share to Neovascularization, Pathologic

Share to Piperidines

Share to Quinazolinones

Source

Identifiers

PMID: 11948962
DOI: 10.1002/pros.10059

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Growth inhibition of prostate cancer xenografts by halofuginone.PMID 11948962Read ↗

Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.Semantic proximity Read ↗

Hormone Therapy Failure in Human Prostate Cancer: Analysis by Complementary DNA and Tissue MicroarraysSemantic proximity Read ↗

U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3.Semantic proximity Read ↗

Eprinomectin: a derivative of ivermectin suppresses growth and metastatic phenotypes of prostate cancer cells by targeting the β-catenin signaling pathway.Semantic proximity Read ↗

Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenograftsSemantic proximity Read ↗

Increased expression of class III β-tubulin in castration-resistant human prostate cancerSemantic proximity Read ↗

Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.Semantic proximity Read ↗

Induction of invasive phenotype by Casodex in hormone-sensitive prostate cancer cells.Semantic proximity Read ↗

H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis.Semantic proximity Read ↗

Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice.Semantic proximity Read ↗

The Role of Serotonin (5-Hydroxytryptamine <sub>1A</sub> and <sub>1B</sub> ) Receptors in Prostate Cancer Cell ProliferationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.